Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
Date:3/5/2009

2008, our management and Board of Directors determined to explore and pursue various restructuring and cost reduction initiatives in order to conserve our liquidity, as well as various financial and strategic transactions that could potentially reduce or eliminate our existing debt obligations and improve our working capital position.

On July 7, 2008, we announced that our Board of Directors had authorized a transaction to create a new subsidiary, Angiotech Pharmaceutical Interventions Inc. ("API"), and that we would contribute certain business assets and intellectual property to API, primarily consisting of business assets of Angiotech other than the intellectual property and royalty revenue related to TAXUS(R) coronary stent systems. In connection with this transaction, we were to receive $200 to $300 million of new financing from new investors to establish API, which financing was targeted to reduce substantial amounts of our existing debt obligations with equivalent amounts of convertible debt bearing interest in additional equity of the newly created subsidiary in kind, as opposed to cash. This transaction, if approved by our shareholders and completed, would have substantially reduced our annual cash pay interest obligations.

On September 22, 2008, we announced that we had postponed the planned shareholder vote regarding the proposed API transaction. As of that date, given the time required for more extended discussions to address concerns of certain of our shareholders and bondholders, and given various other factors impacting our business and cash position (including lower expected revenues derived from BSC), we did not believe we would be able to satisfy the transaction condition with respect to the minimum level of cash and cash equivalents required to be held at the time of the transaction's close.

On September 22, 2008, we also announced that we would pursue various initiatives to reduce operating costs and further focus our busin
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
2. Angiotech Pharmaceuticals announces time change of conference call and webcast
3. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
4. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
5. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
6. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
7. Angiotech wins before the UK House of Lords
8. Angiotech to Establish Separate Operating and Royalty Businesses
9. Angiotech To Commence Cash Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
10. Angiotech announces market launch of Quill(TM) SRS MONODERM(TM)
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... April 16, 2015 Cambridge ... solutions driven by Semantic Web technology, and ... information and services for the academic and scientific, ... its joint solution ‘Smart Data Lake for Clinical ... for the 2015 Bio-IT ‘Best of Show’ Award. ...
(Date:4/16/2015)... (PRWEB) April 16, 2015 Regis Technologies ... American Association for Cancer Research (AACR) annual meeting. Regis ... Convention Center, starting Saturday, April 18, in Philadelphia and ... claim to title of the oldest and largest organization ... fellowships and grants, and partners with survivors to promote ...
(Date:4/16/2015)... TORONTO , April 16, 2015 /PRNewswire/ - Portage ... PTGEF, Canadian Securities Exchange: PBT.U), is pleased to announce ... Investor Show on April 25, 2015 to be held ... Dr. Gregory Bailey and Mr. James ... overview and an update on the key programs at ...
(Date:4/16/2015)... , April 16, 2015  AnaptysBio, Inc., ... of therapeutic antibodies, today announced the advancement ... program into IND-enabling studies. The Company,s anti-IL-36R ... treatment for generalized pustular psoriasis (GPP), an ... medical need. ANB019 is wholly owned within AnaptysBio,s ...
Breaking Biology Technology:Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 2Cambridge Semantics and Informa Named Bio-IT Award Finalist for Smart Data Lake Solution for Clinical Trial and Competitive Intelligence 3Regis Technologies Joins American Association for Cancer Research Annual Meeting 2Portage to Present at Master Investor 2015 in London, UK 2Portage to Present at Master Investor 2015 in London, UK 3Portage to Present at Master Investor 2015 in London, UK 4AnaptysBio Advances First-In-Class Anti-IL-36 Receptor Antibody Program To Treat Orphan Inflammatory Disease 2
... a long-planned departure from its traditional focus, high-end computer ... U.S. Army for development of two different products. , ... it has secured $2.2 million in federal contracts for ... the Armys Research, Development and Engineering Command (CERDEC) to ...
... Inc. for the quarter ended March 31 rose to $142.5 ... company earned the same quarter of 2004. , ,Profit for ... even $150 million, compared to $78.3 million a year ago. ... more than $10 per share Tuesday and Wednesday from Monday's ...
... Milwaukee Merge eFilm , the Milwaukee-based ... Inc., continued to build momentum leading into its proposed ... net sales of just more than $10.5 million in ... first quarter 2004, after a 19 percent year-over-year jump ...
Cached Biology Technology:SLE of Eau Claire lands $2.2 million in federal contracts 2SLE of Eau Claire lands $2.2 million in federal contracts 3Merge eFilm earnings jump precedes planned merger 2Merge eFilm earnings jump precedes planned merger 3
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
Breaking Biology News(10 mins):HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3Synaptics to Report Third Quarter Results on April 23 2Fingerprint Cards Revises Revenues for Q1 2015 2
... controlled trial of fish oil given intravenously to patients ... exchange, reduces inflammatory chemicals and results in a shorter ... open access journal Critical Care investigated the ... solution for patients with sepsis, finding a significant series ...
... 1. Prescribed Opioids Associated with Significant Risk for ... oxycodone, have increased significantly over the past decade. As ... common, the deaths associated with opioids increase. Opioid overdose ... Researchers sought to determine the rate of opioid overdose ...
... MIT and Harvard Medical School have built targeted nanoparticles ... medicine, an advance that potentially provides an alternative to ... The particles, dubbed "nanoburrs" because they are coated with ... target proteins, can be designed to release their drug ...
Cached Biology News:Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 2Annals of Internal Medicine tip sheet for Jan. 19, 2010, issue 3New nanoparticles target cardiovascular disease 2
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... (M-MLV RT) is an RNA-dependent DNA polymerase that ... messenger RNA templates (>5kb). The enzyme is a ... consists of a single subunit with a molecular ... M-MLV RT is weaker than the commonly used ...
... of Cell Cultures (ECACC) in conjunction with ... West of England, Bristol, UK, have produced ... of HER2, oestrogen and progresterone receptor assays. ... of formalin fixed, breast cancer cell lines; ...
... highly potent TURBO DNase (patent pending) in the ... in DNA removal capabilities. TURBO DNase is a ... much more efficient than wild type DNase I ... TURBO DNase binds DNA substrates 6-fold more tightly ...
Biology Products: